Lupus Nephritis Composite Outcome Measure Recommended For Approval
Lupus nephritis surrogate endpoints, including reduction in double-stranded DNA antibodies, are insufficiently developed to stand alone as primary outcomes for studies, FDA's Arthritis Advisory Committee concluded at its meeting Sept. 29
You may also be interested in...
FDA's draft guidance on lupus drug development allows for the use of clinical trials on specific organs to support a broader lupus claim
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011